Hamilton Lane
HLNE
$81.40
-6.67%
Hamilton Lane is a global private markets investment firm, providing solutions to institutional and private wealth investors through discretionary and non-discretionary asset management services. The firm is a distinct, specialized player in the asset management industry, having focused exclusively on private markets for over three decades, which grants it deep expertise and a significant platform with nearly $986 billion in assets under management and supervision. The current investor narrative is likely dominated by the performance of private markets amid a challenging macroeconomic environment, with debates centered on the firm's ability to navigate fundraising cycles, manage fee-related earnings stability, and capitalize on the long-term secular shift of institutional capital into private assets.…
HLNE
Hamilton Lane
$81.40
Investment Opinion: Should I buy HLNE Today?
Rating: Hold. The core thesis is that while HLNE is fundamentally sound and potentially undervalued on a forward earnings basis, powerful negative momentum and sector headwinds warrant caution, making it a 'watchlist' candidate rather than an immediate buy.
Supporting evidence includes a forward P/E of 10.83x, which is low for a company with a 27.23% ROE and 32.83% net margin. The stock trades just 5.5% above its 52-week low, suggesting most bad news may be priced in. However, the severe technical downtrend (-45.32% over 1 year), minimal analyst coverage, and high P/S ratio of 4.86x counterbalance the value argument.
The biggest risks are a breakdown below the $75.93 support level and a further deceleration in private markets activity. This Hold would upgrade to a Buy if the stock establishes a base above $75.93 with improving relative strength, or if forward earnings estimates are revised upward. It would downgrade to a Sell on a confirmed break below $75.93. Relative to its own depressed history, the stock appears fairly valued to slightly undervalued on earnings, but overvalued on sales, indicating the market is skeptical of top-line growth.
Sign up to view all
HLNE 12-Month Price Forecast
HLNE presents a classic 'value trap vs. deep value' dilemma. The fundamentals are strong, but the price action is abysmal. The neutral stance reflects the high probability (55%) of a sideways, base-building year as the market digests the private markets slowdown. The stance would upgrade to bullish on a confirmed technical reversal above $110 with improving relative strength. It would downgrade to bearish on a sustained break below $75.93, which would signal a failure of the value support thesis.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hamilton Lane's 12-month outlook, with a consensus price target around $105.82 and implied upside of +30.0% versus the current price.
Average Target
$105.82
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$65 - $106
Analyst target range
Analyst coverage for HLNE appears extremely limited, with data indicating coverage from only one analyst; this minimal coverage is insufficient to establish a meaningful consensus recommendation, average target price, or a distribution of Buy/Hold/Sell ratings. The implications of such limited coverage are significant: it typically indicates the stock is a smaller or more specialized name with less institutional interest, which can lead to higher volatility, less efficient price discovery, and a greater reliance on company-specific disclosures for investment decisions.
Bulls vs Bears: HLNE Investment Factors
The evidence currently leans bearish, driven by overwhelming negative price momentum, significant sector headwinds, and a lack of institutional support. The bull case rests on deep value metrics, strong profitability, and a healthy balance sheet, suggesting the sell-off may be overdone. The single most important tension in the investment debate is whether the stock's collapse to near its 52-week low represents a capitulation event and a buying opportunity, or if it is a justified reflection of a deteriorating fundamental outlook for private markets fundraising and fee growth. The resolution of this tension hinges on the next few quarters of AUM growth and fee-related earnings stability.
Bullish
- Strong Profitability Margins: The company exhibits robust underlying profitability with a trailing net margin of 32.83% and a gross margin of 69.88%. This indicates a highly efficient fee-based business model capable of converting a significant portion of revenue into earnings.
- Attractive Forward Valuation: The stock trades at a forward P/E of 10.83x, a significant discount to its trailing P/E of 14.80x, implying the market expects earnings growth. This forward multiple suggests the stock is priced for low expectations relative to its profitable profile.
- Healthy Balance Sheet: A debt-to-equity ratio of 0.39 and a current ratio of 1.62 demonstrate a conservative capital structure and strong short-term liquidity. This financial stability provides resilience in a challenging market environment.
- High Return on Equity: A return on equity of 27.23% signifies highly efficient use of shareholder capital to generate profits. This metric is well above typical market averages, highlighting management's operational effectiveness.
Bearish
- Severe Technical Downtrend: The stock is in a pronounced downtrend, down 45.32% over the past year and underperforming the SPY by 68.18 percentage points. With a beta of 1.157, its higher volatility has amplified losses, and momentum remains negative with a 7.66% decline over the past month.
- Minimal Analyst Coverage: The stock is covered by only one analyst, indicating low institutional interest and potentially inefficient price discovery. This lack of coverage increases reliance on company-specific news and can lead to higher volatility and liquidity risk.
- Sector & Macro Headwinds: As a private markets specialist, HLNE is highly sensitive to fundraising cycles and capital flows, which are currently challenged by high interest rates. The stock's dramatic underperformance suggests the market is pricing in a prolonged slowdown in private market activity.
- Valuation Compression Risk: Despite a low forward P/E, the stock's price-to-sales ratio of 4.86 and price-to-book ratio of 4.03 are elevated for a financial services firm. If growth expectations falter, these multiples could compress further, pressuring the stock price.
HLNE Technical Analysis
The stock is in a pronounced and sustained downtrend, having declined 45.32% over the past year and currently trading at approximately 49.7% of its 52-week range, positioned much closer to its 52-week low of $75.93 than its high of $161.13. This positioning near the lower bound of its annual range suggests the stock is in a deep value territory but also reflects significant negative momentum and investor pessimism, raising the risk of it being a 'falling knife' rather than a clear opportunity. Recent momentum remains decisively negative, with the stock down 7.66% over the past month and 17.29% over the past three months, which aligns with and reinforces the longer-term downtrend, indicating no meaningful divergence or sign of a reversal at this stage. The stock's beta of 1.157 indicates it is approximately 16% more volatile than the broader market (SPY), which has compounded losses for investors as the stock has dramatically underperformed the SPY's 22.86% 1-year gain by 68.18 percentage points. Key technical support is at the 52-week low of $75.93, while resistance is far above at the 52-week high of $161.13; a breakdown below $75.93 would signal a continuation of the bearish trend, whereas any recovery would first need to contend with overhead supply from investors trapped in the steep decline.
Beta
1.16
1.16x market volatility
Max Drawdown
-55.5%
Largest decline past year
52-Week Range
$76-$161
Price range past year
Annual Return
-40.1%
Cumulative gain past year
| Period | HLNE Return | S&P 500 |
|---|---|---|
| 1m | -6.2% | +0.3% |
| 3m | -19.4% | +12.3% |
| 6m | -39.4% | +8.9% |
| 1y | -40.1% | +24.0% |
| ytd | -40.4% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HLNE Fundamental Analysis
Revenue and growth trajectory analysis is constrained as specific quarterly revenue figures and year-over-year growth rates are not available in the provided data, preventing a detailed assessment of whether growth is accelerating or decelerating; however, the company's business model is heavily tied to assets under management, which are substantial at nearly $986 billion. The company is profitable with a trailing net margin of 32.83% and a robust gross margin of 69.88%, indicating strong underlying fee-based profitability on its services; the operating margin of 42.81% further demonstrates efficient cost management relative to its revenue base. The balance sheet appears healthy with a current ratio of 1.62, suggesting good short-term liquidity, and a moderate debt-to-equity ratio of 0.39, which implies a conservative use of leverage; the return on equity of 27.23% is strong, indicating efficient use of shareholder capital to generate profits.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HLNE Overvalued?
Given the company's clear profitability, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The stock trades at a trailing P/E of 14.80x and a forward P/E of 10.83x; the gap between these multiples suggests the market anticipates earnings growth, as the forward multiple implies a lower price relative to expected future profits. A direct peer comparison is not possible as industry average valuation multiples were not provided in the data, preventing an assessment of whether HLNE trades at a premium or discount to its asset management sector. Historical context is also unavailable due to missing historical ratios data, so it cannot be determined if the current P/E of 14.80x is near the top or bottom of the stock's own historical range, which would help gauge if the market's expectations are optimistic or pessimistic.
PE
14.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is revenue concentration in private markets, which are cyclical and sensitive to capital flows. While the company is profitable with a 32.83% net margin, its earnings are directly tied to nearly $986 billion in AUM, making it vulnerable to valuation markdowns and reduced transaction activity in a downturn. The moderate debt level (D/E of 0.39) is manageable, but a sustained decline in management fees could pressure the high operating margin of 42.81%.
Market & Competitive Risks: The stock faces significant valuation compression risk, trading at a forward P/E of 10.83x but a P/S of 4.86x, which is high for asset managers. Its beta of 1.157 indicates it is 16% more volatile than the market, which has compounded losses as it underperformed the SPY by 68% over the past year. Competitive risks include larger, diversified asset managers encroaching on private markets and the potential for a prolonged 'higher-for-longer' rate environment suppressing investor appetite for illiquid alternatives.
Worst-Case Scenario: The worst-case scenario involves a severe recession leading to a freeze in private capital fundraising, significant mark-to-market losses on existing fund holdings, and client redemptions. This could trigger a downward spiral in fee-related earnings. Realistic downside could see the stock break its 52-week low of $75.93 and approach levels implied by a 30-35% decline from the current price, representing a potential loss of -30% to -35% for investors buying at $80.10.
FAQ
The key risks are: 1) Market/Sector Risk: The stock's fate is tied to private markets fundraising, which is highly sensitive to interest rates and economic sentiment (evidenced by 45.32% annual decline). 2) Technical/Momentum Risk: The stock is in a severe downtrend with a beta of 1.157, meaning continued market volatility will likely amplify moves. 3) Liquidity & Coverage Risk: Coverage by only one analyst leads to less efficient price discovery and higher volatility. 4) Valuation Risk: Elevated P/S and P/B ratios could compress further if growth stalls. The sector/market risk is currently the most severe, driving the overwhelming negative momentum.
The 12-month forecast is highly bifurcated, with a 55% probability base case target range of $90-$105, implying a 12-31% upside from $80.10. The 25% probability bull case sees a rally to $120-$135 on a sector recovery, while the 20% probability bear case warns of a drop to $70-$80 if support fails. The base case is most likely, assuming the stock consolidates in a range as the private markets environment stabilizes without a sharp recovery. The key assumption is that the company's high profitability prevents a more severe earnings collapse.
HLNE sends mixed valuation signals. On a forward earnings basis, it appears undervalued with a P/E of 10.83x, especially given its high return on equity of 27.23%. However, on a price-to-sales basis (P/S of 4.86), it trades at a premium typical of growth companies, which is at odds with its current negative growth narrative. Compared to its own 52-week high, it is deeply undervalued. Overall, the stock is fairly valued to slightly undervalued if current earnings estimates hold, but the market is clearly pricing in significant skepticism about future revenue growth, implying a 'show me' story is required.
HLNE is a high-risk, potentially high-reward stock that is not a good buy for most investors at this moment. For a specialized, contrarian investor, the forward P/E of 10.83x and strong profitability metrics (32.83% net margin) are compelling against a backdrop of a 45% price decline. However, the severe downtrend, lack of analyst coverage, and sector headwinds make the timing exceptionally difficult. It could be a good buy for a patient investor only after the stock shows technical evidence of basing, such as holding above $75.93 and demonstrating improved relative strength.
HLNE is unsuitable for short-term trading due to its high volatility (beta 1.157), negative momentum, and lack of near-term catalysts. It is a speculative long-term investment for investors who believe in the multi-decade secular trend of institutional capital allocation to private markets. A minimum holding period of 3-5 years is suggested to potentially ride out the current cycle and allow the firm's platform strength and profitability to drive a recovery. The modest 3.85% dividend yield provides a small income cushion but is not sufficient to justify the stock as a primary income holding.